Arbutus to report third quarter 2021 financial results and provide corporate update

Warminster, pa., oct. 21, 2021 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis b virus (hbv) infection and to treat coronaviruses (including covid-19), today announced that it has scheduled its third quarter 2021 financial results and corporate update for thursday, november 4, 2021. the schedule for the press release and conference call/webcast are as follows:
ABUS Ratings Summary
ABUS Quant Ranking